Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma.

ABSTRACT:

Purpose

The CheckMate 066 trial investigated nivolumab monotherapy as first-line treatment for patients with previously untreated BRAF wild-type advanced melanoma. Five-year results are presented herein.

Patients and methods

In this multicenter, double-blind, phase III study, 418 patients with previously untreated, unresectable, stage III/IV, wild-type BRAF melanoma were randomly assigned 1:1 to receive nivolumab 3 mg/kg every 2 weeks or dacarbazine 1,000 mg/m² every 3 weeks. The primary end point was overall survival (OS), and secondary end points included progression-free survival (PFS), objective response rate (ORR), and safety.

Results

Patients were followed for a minimum of 60 months from the last patient randomly assigned (median follow-

SUBMITTER: Robert C 

PROVIDER: S-EPMC7676881 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature